S

Svas Biosana SpA
MIL:SVS

Watchlist Manager
Svas Biosana SpA
MIL:SVS
Watchlist
Price: 9.1 EUR -0.66% Market Closed
Market Cap: €48.5m

Svas Biosana SpA
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Svas Biosana SpA
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
S
Svas Biosana SpA
MIL:SVS
Net Issuance of Common Stock
-€310k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Ivision Tech SpA
MIL:IVN
Net Issuance of Common Stock
€1.3m
CAGR 3-Years
47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Svas Biosana SpA
Glance View

Market Cap
48.5m EUR
Industry
Health Care

Svas Biosana SpA distributes medical appliances. The company is headquartered in Somma Vesuviana, Napoli and currently employs 367 full-time employees. The company went IPO on 2021-12-09. The firm consists of four divisions namely: Farmex division, manufactures range of gauze and cotton made products; Medical division, provides suction line, infusion line, and custom packs; Svas division, provides own brand products, specialities, galenic solutions and disposables; and Harvest division, provides electromedical equipments, after-sales technical services. The firm is the subsidiary of Svas group. Test Data.

SVS Intrinsic Value
14.82 EUR
Undervaluation 39%
Intrinsic Value
Price €9.1
S

See Also

What is Svas Biosana SpA's Net Issuance of Common Stock?
Net Issuance of Common Stock
-310k EUR

Based on the financial report for Dec 31, 2024, Svas Biosana SpA's Net Issuance of Common Stock amounts to -310k EUR.

What is Svas Biosana SpA's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 1Y
30%

Over the last year, the Net Issuance of Common Stock growth was 30%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett